In liver cancer, the nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor (TF) stimulates the expression of several reductases that can inhibit ferroptosis by reducing ROS accumulation, and an increase in the proto-oncoprotein p62 inhibits NRF2 degradation, which in turn boosts NRF2 transcription activity (Chen et al., 2023; Yan et al., 2023). Here, NFE2L2 is linked to liver cancer.